2023

1. Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study

   The Lancet. Oncology, Vol. 24, Núm. 12, pp. 1411-1422